"UPMC Hillman Cancer Center at John P. Murtha Pavilion (Radiation Oncology) is a Cancer Treatment Center located in Johnstown.Visit our website to learn more about the conditions we treat and the services we offer. Schedule your appointment today. UPMC is committed to protecting our communities from the spread of COVID-19. We continue to require people who come to any UPMC facility to wear a facemask that covers their nose and mouth and to practice other preventative efforts like social distancing, even if fully vaccinated."

During the past decade, UPMC-Johnstown/John P. Murtha Regional Cancer Center conducted 60 clinical trials. In the 10-year time frame, 60 clinical trials started and 39 clinical trials were completed, i.e. on average, 65% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 30 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UPMC-Johnstown/John P. Murtha Regional Cancer Center" #1 sponsor was "National Cancer Institute (NCI)" with 37 trials, followed by "Alliance for Clinical Trials in Oncology" with 15 trials sponsored, "SWOG Cancer Research Network" with 14 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 7 trials sponsored and "NRG Oncology" with 7 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UPMC-Johnstown/John P. Murtha Regional Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 49 trials as a collaborator, "NRG Oncology" with 18 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "Radiation Therapy Oncology Group" with 2 trials as a collaborator and "Amgen" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "UPMC-Johnstown/John P. Murtha Regional Cancer Center" are "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials), "Stage IIIA Breast Cancer" (6 trials), "Invasive Breast Carcinoma" (5 trials) and "Stage II Breast Cancer" (5 trials). Many other conditions were trialed in "UPMC-Johnstown/John P. Murtha Regional Cancer Center" in a lesser frequency.

Most popular intervention types in "UPMC-Johnstown/John P. Murtha Regional Cancer Center" are "Drug" (76 trials), "Other" (58 trials), "Biological" (33 trials), "Radiation" (29 trials) and "Procedure" (25 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (33 trials), "Quality-of-Life Assessment" (23 trials), "Cisplatin" (15 trials), "Computed Tomography" (14 trials) and "Docetaxel" (13 trials). Other intervention names were less common.

The vast majority of trials in "UPMC-Johnstown/John P. Murtha Regional Cancer Center" are 71 trials for "All" genders, 12 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "UPMC-Johnstown/John P. Murtha Regional Cancer Center". undefined are not yet recruiting, 21 are recruiting, 40 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in UPMC-Johnstown/John P. Murtha Regional Cancer Center, 3 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in UPMC-Johnstown/John P. Murtha Regional Cancer Center, 0 "Phase 1" clinical trials were conducted, 44 "Phase 2" clinical trials and 56 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".